Free Trial

Keros Therapeutics (KROS) Competitors

$47.44
+1.47 (+3.20%)
(As of 07/12/2024 ET)

KROS vs. SRRA, SRRK, YMAB, DRNA, AMRN, VKTX, MDGL, SMMT, CYTK, and OGN

Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Sierra Oncology (SRRA), Scholar Rock (SRRK), Y-mAbs Therapeutics (YMAB), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Viking Therapeutics (VKTX), Madrigal Pharmaceuticals (MDGL), Summit Therapeutics (SMMT), Cytokinetics (CYTK), and Organon & Co. (OGN). These companies are all part of the "medical" sector.

Keros Therapeutics vs.

Keros Therapeutics (NASDAQ:KROS) and Sierra Oncology (NASDAQ:SRRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking.

Keros Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Sierra Oncology has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500.

Keros Therapeutics currently has a consensus price target of $88.29, suggesting a potential upside of 86.10%. Given Keros Therapeutics' higher possible upside, equities analysts clearly believe Keros Therapeutics is more favorable than Sierra Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Keros Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sierra Oncology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Sierra Oncology has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Sierra Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Keros Therapeutics$150K11,410.90-$152.99M-$5.15-9.21
Sierra Oncology$300K4,476.00-$94.66M-$6.77-8.12

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Sierra Oncology shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by insiders. Comparatively, 44.1% of Sierra Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sierra Oncology received 258 more outperform votes than Keros Therapeutics when rated by MarketBeat users. However, 68.25% of users gave Keros Therapeutics an outperform vote while only 67.49% of users gave Sierra Oncology an outperform vote.

CompanyUnderperformOutperform
Keros TherapeuticsOutperform Votes
43
68.25%
Underperform Votes
20
31.75%
Sierra OncologyOutperform Votes
301
67.49%
Underperform Votes
145
32.51%

In the previous week, Keros Therapeutics had 1 more articles in the media than Sierra Oncology. MarketBeat recorded 1 mentions for Keros Therapeutics and 0 mentions for Sierra Oncology. Keros Therapeutics' average media sentiment score of 1.89 beat Sierra Oncology's score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Keros Therapeutics Very Positive
Sierra Oncology Neutral

Keros Therapeutics' return on equity of -45.53% beat Sierra Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Keros TherapeuticsN/A -45.53% -41.68%
Sierra Oncology N/A -111.88%-100.01%

Summary

Keros Therapeutics beats Sierra Oncology on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KROS vs. The Competition

MetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.71B$7.31B$5.40B$8.73B
Dividend YieldN/A2.73%2.77%4.03%
P/E Ratio-9.2111.33107.2315.45
Price / Sales11,410.90289.012,172.4479.91
Price / CashN/A33.2136.3233.15
Price / Book4.285.844.944.46
Net Income-$152.99M$146.83M$111.45M$215.59M
7 Day Performance12.39%10.49%6.19%5.35%
1 Month Performance-3.89%6.45%5.70%4.39%
1 Year Performance16.70%0.03%6.50%1.77%

Keros Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SRRA
Sierra Oncology
0 of 5 stars
0.00 / 5 stars
$54.99
flat
N/AN/A$1.34B$300,000.00-8.12109
SRRK
Scholar Rock
4.3969 of 5 stars
4.40 / 5 stars
$8.93
+8.0%
$26.00
+191.2%
+30.6%$712.20M$33.19M-4.27150Positive News
Gap Up
YMAB
Y-mAbs Therapeutics
2.4053 of 5 stars
2.41 / 5 stars
$12.07
+4.5%
$17.86
+47.9%
+76.4%$529.67M$84.50M-24.63100Positive News
Gap Up
DRNA
Dicerna Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
$38.22
flat
N/AN/A$2.99B$164.31M-23.45302Analyst Forecast
AMRN
Amarin
0.9857 of 5 stars
0.99 / 5 stars
$0.75
-1.3%
$1.08
+45.3%
-36.0%$311.50M$277.46M-6.22275Positive News
VKTX
Viking Therapeutics
4.3799 of 5 stars
4.38 / 5 stars
$58.63
+1.1%
$111.56
+90.3%
+263.3%$6.47BN/A-63.0428Short Interest ↑
News Coverage
MDGL
Madrigal Pharmaceuticals
4.4022 of 5 stars
4.40 / 5 stars
$290.32
+2.1%
$348.17
+19.9%
+27.3%$6.19BN/A-12.57376Analyst Upgrade
SMMT
Summit Therapeutics
2.0379 of 5 stars
2.04 / 5 stars
$8.68
+4.7%
$13.50
+55.5%
+288.6%$6.09B$700,000.00-54.25105Short Interest ↓
News Coverage
Positive News
CYTK
Cytokinetics
4.1341 of 5 stars
4.13 / 5 stars
$56.30
+2.5%
$77.06
+36.9%
+57.7%$5.90B$3.75M-10.43423Insider Selling
Short Interest ↑
News Coverage
OGN
Organon & Co.
4.0687 of 5 stars
4.07 / 5 stars
$20.89
+4.9%
$22.60
+8.2%
+2.8%$5.37B$6.26B5.1110,000Positive News

Related Companies and Tools

This page (NASDAQ:KROS) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners